2nd April 2010 - News release

It has been claimed that Stalevo, which is used for  the treatment of Parkinsonís disease, may be linked to an increased risk of prostate cancer. Stalevo is a combination of L-dopa, carbidopa, and entacapone. For more information go to Stalevo. Entacapone is also available as a single-product ingredient called Comtan. The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data suggesting that patients taking Stalevo, may be at an increased risk for developing prostate cancer. The number of people taking Stalevo with prostate cancer was small, but it was still four times what would otherwise be expected. The FDA's review of Stalevo is ongoing and so no new conclusions or recommendations about the use of this drug have been made. They consequently suggest that "Patients should not stop taking their medication unless directed to do so by their healthcare professional". For more information go to the News release. For more current news go to Parkinson's Disease News.


E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports





©2006-2010  Viartis
2015-11-09 22:01:05
[email protected]